CSTL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Castle Biosciences Reports Third Quarter 2026 Results and Raises Full-Year Revenue Guidance

Nov 5, 2026

8-K

Castle Biosciences Reports Second Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

Jul 30, 2026

8-K

Castle Biosciences, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 29, 2026

8-K

Castle Biosciences Reports First Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

May 6, 2026

8-K

Castle Biosciences Reports Strong 2025 Results, Exceeding Guidance with $344M Revenue and Significant Test Volume Growth

Feb 26, 2026

8-K

Castle Biosciences Reports Strong Preliminary Results for Q4 and Full Year 2025

Jan 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

4,000,000 Shares-

Dec 16, 2020

424B5

Common Stock-

Dec 14, 2020

424B4

2,000,000 Shares

Jun 25, 2020

424B4

4,000,000 Shares

Jul 25, 2019

Registrations

TYPE

HEADLINE

FILED AT

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Aug 14, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-8

Common Stock

Feb 28, 2024

S-3

SHELF | Offering amount: $300,000,000.00 EFFECTIVE

Feb 28, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 8, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 10, 2024

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

MAETZOLD DEREK J (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 2, 2026

Juvenal Tobin W (Reporting)

Oct 30, 2026

SCHEDULE 13G/A

PRINCIPAL GLOBAL INVESTORS (Filed by)

Oct 29, 2026

Juvenal Tobin W (Reporting)

Oct 28, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 17, 2024

CORRESP

Form CORRESP - Correspondence

Apr 12, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 7, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 25, 2020

CORRESP

Form CORRESP - Correspondence

Jun 22, 2020

CORRESP

Form CORRESP - Correspondence

Jun 22, 2020

Castle Biosciences, Inc. CSTL · SEC Filings